Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the period of November 2019, specifically dated November 14, 2019. The company is a foreign private issuer based in Jena, Germany, focused on developing the first-in-class anti-C5a antibody IFX-1.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to update an investor presentation and does not contain financial statements or specific financial data points.
Material Changes
The material change reported is the update of the company's investor presentation (the "Deck") titled "Developing the First in Class Anti-C5a Antibody IFX-1: Lessons Learned from Clinical Trials." No financial or operational changes are detailed in the text of this filing.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the updated presentation, which is incorporated by reference and available on the company website. The filing text does not provide specific guidance, outlook, risks, contingencies, or unusual items; these details are contained within the attached Exhibit 99.1 presentation.
Key Facts for Investor Verification
- Verify the content of the updated November 2019 presentation (Exhibit 99.1) for clinical trial updates and strategic direction.
- Confirm the availability of the presentation on the company website (www.inflarx.de).
- Note that this filing contains no financial data; refer to Form 20-F for audited financial statements.